利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.037 秒)

    Agent containing ergoline for transdermal application
    1.
    发明申请
    Agent containing ergoline for transdermal application 审中-公开
    含麦角林的药物用于经皮应用

    公开(公告)号：US20070134309A1

    公开(公告)日：2007-06-14

    申请号：US10570262

    申请日：2004-05-30

    申请人： Reinhard Horowski ,  Johannes Tack ,  Katalin Bostedt ,  Dirk Schenk

    发明人： Reinhard Horowski ,  Johannes Tack ,  Katalin Bostedt ,  Dirk Schenk

    IPC分类号： A61K9/70

    CPC分类号： A61K9/7061 ,  A61K31/48 ,  A61K47/10

    摘要： The invention relates to a transdermal therapeutic system containing ergolin compounds, preferably lisuride, in which the ergolin compound is stabilized. The oxidation-sensitive ergolin compound is stabilized by a combination of at least one liposoluble, free radical-scavenging antioxidant, preferably di-tert.-butyl methyl phenol, di-tert.-butyl metoxy phenol, tocopherol or ubiquinone and a basic polymer.

    摘要翻译： 本发明涉及一种含有麦角蛋白化合物，优选碘化镧的透皮治疗系统，其中麦角蛋白化合物稳定化。 氧化敏感的麦角蛋白化合物通过至少一种脂溶性自由基清除抗氧化剂，优选二叔丁基甲基苯酚，二叔丁基甲氧基苯酚，生育酚或泛醌和碱性聚合物的组合来稳定。

    Transdermal therapeutic system
    2.
    发明申请
    Transdermal therapeutic system 审中-公开

    公开(公告)号：US20060105030A1

    公开(公告)日：2006-05-18

    申请号：US11087754

    申请日：2005-03-24

    申请人： Fred Windt-Hanke ,  Clemens Gunther ,  Reinhard Horowski ,  Johannes Tack ,  Adalbert Engfer ,  Katalin Bostedt ,  Dirk Schenk

    发明人： Fred Windt-Hanke ,  Clemens Gunther ,  Reinhard Horowski ,  Johannes Tack ,  Adalbert Engfer ,  Katalin Bostedt ,  Dirk Schenk

    IPC分类号： A61K9/70

    CPC分类号： A61K9/7061 ,  A61K9/7053 ,  A61K31/48

    摘要： The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the Restless Leg Syndrome and Periodic Limb Movement Disorder. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

    Transdermal therapeutic system
    3.
    发明申请
    Transdermal therapeutic system 审中-公开

    公开(公告)号：US20070243240A9

    公开(公告)日：2007-10-18

    申请号：US11087754

    申请日：2005-03-24

    申请人： Fred Windt-Hanke ,  Clemens Gunther ,  Reinhard Horowski ,  Johannes Tack ,  Adalbert Engfer ,  Katalin Bostedt ,  Dirk Schenk

    发明人： Fred Windt-Hanke ,  Clemens Gunther ,  Reinhard Horowski ,  Johannes Tack ,  Adalbert Engfer ,  Katalin Bostedt ,  Dirk Schenk

    IPC分类号： A61K9/70

    CPC分类号： A61K9/7061 ,  A61K9/7053 ,  A61K31/48

    摘要： The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the Restless Leg Syndrome and Periodic Limb Movement Disorder. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

    TRANSDERMAL THERAPEUTIC SYSTEM WITH TWO-PHASE RELEASE PROFILE
    5.
    发明申请
    TRANSDERMAL THERAPEUTIC SYSTEM WITH TWO-PHASE RELEASE PROFILE 审中-公开
    具有两相释放特性的超导治疗系统

    公开(公告)号：US20100143475A1

    公开(公告)日：2010-06-10

    申请号：US12311305

    申请日：2007-08-27

    申请人： Johannes Tack ,  Björn Schurad ,  Antje Müller-Schubert ,  Reinhard Horowski

    发明人： Johannes Tack ,  Björn Schurad ,  Antje Müller-Schubert ,  Reinhard Horowski

    IPC分类号： A61K31/48 ,  A61K9/00 ,  A61P25/16 ,  A61P25/14 ,  A61P25/00

    CPC分类号： A61K9/7061 ,  A61K31/48

    摘要： The present invention relates to a transdermal therapeutic system (TTS) consisting of an impermeable coating, a matrix containing an ergoline compound having the formula (I) or a physiologically compatible salt or derivative thereof, wherein R1 denotes an H atom or a halogen atom and R2 is an alkyl group having 1 to 4 carbon atoms and denotes a single or double bond, and a removable protective layer, wherein the ergoline compound or a physiologically compatible salt or derivative thereof is stabilised by an antioxidant and a basic polymer. The TTS is characterised in that the matrix contains at least one hydrocarbon having 8 to 18 carbon atoms in a straight or branched chain, which has a functional group at the end of the alkyl chain and/or Aloe Vera, so that in a first phase (0-5 hours after application) only 0-20% of the therapeutically desired steady-state plasma concentration of the ergoline compound is achieved and the therapeutically desired steady-state plasma concentration of the ergoline compound is only achieved in a second phase (5-20 hours after application).

    摘要翻译： 本发明涉及一种由不透水涂层组成的透皮治疗系统（TTS），含有式（I）的麦角灵化合物或其生理上相容的盐或衍生物的基质，其中R1表示H原子或卤素原子， R2是具有1至4个碳原子并且表示单键或双键的烷基和可除去的保护层，其中麦角灵化合物或其生理上相容的盐或其衍生物由抗氧化剂和碱性聚合物稳定。 TTS的特征在于，基质含有至少一个在直链或支链上具有8至18个碳原子的烃，其在烷基链和/或芦荟末端具有官能团，因此在第一相中 （施用后0-5小时）仅实现治疗期望的稳态血浆浓度的0〜20％的麦角灵化合物，并且仅在第二阶段（5）中实现麦角灵化合物的治疗期望的稳态血浆浓度 应用后-20小时）。

    Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
    6.
    发明授权
    Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states 失效
    透皮治疗系统和含多巴胺激动剂的口服和/或肠胃外制剂的组合用于治疗多巴胺能疾病状态

    公开(公告)号：US07258871B2

    公开(公告)日：2007-08-21

    申请号：US10362182

    申请日：2001-08-24

    申请人： Reinhard Horowski ,  Johannes Tack

    发明人： Reinhard Horowski ,  Johannes Tack

    IPC分类号： A61K9/70 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48

    CPC分类号： A61K9/7061 ,  A61K31/48

    摘要： The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

    摘要翻译： 本发明涉及由至少两个空间上分散的组合物组成的药剂形式的多巴胺激动剂的用途，其中一种是含有多巴胺能药物的透皮治疗系统（TTS），另一种是另外一种或多种用于口服和 /或肠胃外应用，其含有用于治疗多巴胺可治疗疾病的相同多巴胺能药物，其具有以下元件：a）连续施用TTS，b）在施用期间内，a）施用用于口服或非肠道给药的组合物。

    Pharmaceutical Compositions for the Treatment of Capillary Arteriopathy
    8.
    发明申请
    Pharmaceutical Compositions for the Treatment of Capillary Arteriopathy 有权
    用于治疗毛细血管病变的药物组合物

    公开(公告)号：US20140045879A1

    公开(公告)日：2014-02-13

    申请号：US13354832

    申请日：2012-01-20

    申请人： Rudolf Reiter ,  Johannes Tack ,  Reinhard Horowski

    发明人： Rudolf Reiter ,  Johannes Tack ,  Reinhard Horowski

    IPC分类号： C07D471/06

    CPC分类号： C07D471/06 ,  A61K31/00 ,  A61K31/48

    摘要： The present invention relates to the use of ergot derivatives or ergolines, and in particular of lisuride and terguride for the prophylaxis and treatment of constrictive capillary arteriopathy. Constrictive capillary arteriopathy refers to the diseases pulmonary arterial hypertension, endogenously induced or exogenously induced glomeruloscleroses as well as secondary Raynaud's syndrome.

    摘要翻译： 本发明涉及麦角衍生物或麦角蛋白，特别是利鲁司特和替麦格德用于预防和治疗缩窄性毛细血管病变的用途。 狭窄性毛细血管动脉病是指肺动脉高压，内源诱导或外源性诱导的肾小球硬化以及继发性雷诺综合征的疾病。